505 results
Mastering the future of PCI with drug-coated balloons
16 May 2024 – From EuroPCR 2024
Join this session dedicated to drug-coated balloons (DCB) to delve into the evolution of angioplasty with DCBs in the U.S. Learn about the established standard of care, balancing efficacy and safety in treating in-stent restenosis (ISR). Gain insights into the fundamental principles of angioplasty with DCB...
Sirolimus-coated balloon: exploring the case- and clinical-based evidences
16 May 2024 – From EuroPCR 2024
Browse this EuroPCR 2024 session to explore the safety and efficacy of sirolimus-coated balloons from pre-clinical data, review MagicTouch data from real-world populations with case-based examples, and learn about the MagicTouch sirolimus-coated balloon clinical programs. Discover insights and takeaways from the significance of the EASTBOURNE subgroups,...
Restoring vessel physiology drives outcomes - The Bioadaptor experience
16 May 2024 – From EuroPCR 2024
Join this session to delve into the unmet needs concerning drug-eluting stents (DES), including poor long-term clinical outcomes, with up to a 50% MACE rate at 10 years, and a non-plateauing 2-3% annual event rate. Explore how DynamX Bioadaptor technology addresses these challenges by maintaining the...
Physiology guided post-DCB treatment to safely limit stenting. Validation in complex clinical settings with the optical Optowire III pressure guidewire
16 May 2024 – From EuroPCR 2024
Follow this session to discover how accurate resting index can inform decision-making for DCB in CTO patients and understand the role of physiology in a new PCI workflow for complex MVD. Thus, you will learn about a DCB intention-to-treat strategy guided by post-PCI coronary physiology in...
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
PCI complications: device-related issues, perforations and other unexpected events
15 May 2024 – From EuroPCR 2024
This session focuses on the management of various complications that can occur during percutaneous coronary intervention (PCI), including device-related issues, perforations, and other unexpected events. Attendees will learn from case presentations and discussions on strategies to identify, mitigate, and manage these complications, with a focus on...
DCB PCI for de novo lesions: when and how?
15 May 2024 – From EuroPCR 2024
In this session, you will learn how to optimally perform DCB PCI, identify which lesions are best suited for this approach, and understand when it's necessary to switch from DCB to stent PCI. The session also features a debate on whether DCB-PCI should be the first...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
An image is worth a 1,000 words
15 May 2024 – From EuroPCR 2024
Randomised trials: substudies and extended follow-up - A quick update
15 May 2024 – From EuroPCR 2024
This session provides a quick update on various randomised trials, including substudies and extended follow-up data. It covers insights on bifurcation stenting, the symptom-stratified analysis of ORBITA-2, the impact of completeness of revascularisation on clinical outcomes from REVIVED-BCIS2, cost-effectiveness of CABG vs. PCI from FAME 3,...
